133 related articles for article (PubMed ID: 35963816)
1. Inhibition of SerpinB9 to enhance granzyme B-based tumor therapy by using a modified biomimetic nanoplatform with a cascade strategy.
Han R; Yu L; Zhao C; Li Y; Ma Y; Zhai Y; Qian Z; Gu Y; Li S
Biomaterials; 2022 Sep; 288():121723. PubMed ID: 35963816
[TBL] [Abstract][Full Text] [Related]
2. Direct Tumor Killing and Immunotherapy through Anti-SerpinB9 Therapy.
Jiang L; Wang YJ; Zhao J; Uehara M; Hou Q; Kasinath V; Ichimura T; Banouni N; Dai L; Li X; Greiner DL; Shultz LD; Zhang X; Sun ZJ; Curtin I; Vangos NE; Yeoh ZC; Geffken EA; Seo HS; Liu ZX; Heffron GJ; Shah K; Dhe-Paganon S; Abdi R
Cell; 2020 Nov; 183(5):1219-1233.e18. PubMed ID: 33242418
[TBL] [Abstract][Full Text] [Related]
3. A novel Granzyme B nanoparticle delivery system simulates immune cell functions for suppression of solid tumors.
Qian X; Shi Z; Qi H; Zhao M; Huang K; Han D; Zhou J; Liu C; Liu Y; Lu Y; Yuan X; Zhao J; Kang C
Theranostics; 2019; 9(25):7616-7627. PubMed ID: 31695790
[TBL] [Abstract][Full Text] [Related]
4. The granzyme B-Serpinb9 axis controls the fate of lymphocytes after lysosomal stress.
Bird CH; Christensen ME; Mangan MS; Prakash MD; Sedelies KA; Smyth MJ; Harper I; Waterhouse NJ; Bird PI
Cell Death Differ; 2014 Jun; 21(6):876-87. PubMed ID: 24488096
[TBL] [Abstract][Full Text] [Related]
5. Serpinb9 (Spi6)-deficient mice are impaired in dendritic cell-mediated antigen cross-presentation.
Rizzitelli A; Meuter S; Vega Ramos J; Bird CH; Mintern JD; Mangan MS; Villadangos J; Bird PI
Immunol Cell Biol; 2012 Oct; 90(9):841-51. PubMed ID: 22801574
[TBL] [Abstract][Full Text] [Related]
6. A Novel Serpin Regulatory Mechanism: SerpinB9 IS REVERSIBLY INHIBITED BY VICINAL DISULFIDE BOND FORMATION IN THE REACTIVE CENTER LOOP.
Mangan MS; Bird CH; Kaiserman D; Matthews AY; Hitchen C; Steer DL; Thompson PE; Bird PI
J Biol Chem; 2016 Feb; 291(7):3626-38. PubMed ID: 26670609
[TBL] [Abstract][Full Text] [Related]
7. Activatable Immunoprotease Nanorestimulator for Second Near-Infrared Photothermal Immunotherapy of Cancer.
Xu M; Zhang C; He S; Xu C; Wei X; Pu K
ACS Nano; 2023 May; 17(9):8183-8194. PubMed ID: 37122103
[TBL] [Abstract][Full Text] [Related]
8. EGFR-targeted granzyme B expressed in NK cells enhances natural cytotoxicity and mediates specific killing of tumor cells.
Oberoi P; Jabulowsky RA; Bähr-Mahmud H; Wels WS
PLoS One; 2013; 8(4):e61267. PubMed ID: 23573299
[TBL] [Abstract][Full Text] [Related]
9. Intrahepatic lymphocyte expression of dipeptidyl peptidase I-processed granzyme B and perforin induces hepatocyte expression of serine proteinase inhibitor 6 (Serpinb9/SPI-6).
Stout-Delgado HW; Getachew Y; Miller BC; Thiele DL
J Immunol; 2007 Nov; 179(10):6561-7. PubMed ID: 17982045
[TBL] [Abstract][Full Text] [Related]
10. Intracellular serine protease inhibitor SERPINB4 inhibits granzyme M-induced cell death.
de Koning PJ; Kummer JA; de Poot SA; Quadir R; Broekhuizen R; McGettrick AF; Higgins WJ; Devreese B; Worrall DM; Bovenschen N
PLoS One; 2011; 6(8):e22645. PubMed ID: 21857942
[TBL] [Abstract][Full Text] [Related]
11. Serpinb9 is a marker of antigen cross-presenting dendritic cells.
Mangan MS; Vega-Ramos J; Joeckel LT; Mitchell AJ; Rizzitelli A; Roediger B; Kaiserman D; Weninger WW; Villadangos JA; Bird PI
Mol Immunol; 2017 Feb; 82():50-56. PubMed ID: 28024184
[TBL] [Abstract][Full Text] [Related]
12. Co-encapsulation of granzyme B and perforin in nanocapsules for tumour therapy: biomimicking immune cells.
Shi Z; Yan J; Zhao M; Li S; She T; Qian X
J Control Release; 2024 May; 369():658-667. PubMed ID: 38604384
[TBL] [Abstract][Full Text] [Related]
13. Design and characterization of a novel human Granzyme B inhibitor.
Marcet-Palacios M; Ewen C; Pittman E; Duggan B; Carmine-Simmen K; Fahlman RP; Bleackley RC
Protein Eng Des Sel; 2015 Jan; 28(1):9-17. PubMed ID: 25492933
[TBL] [Abstract][Full Text] [Related]
14. Control of granzymes by serpins.
Kaiserman D; Bird PI
Cell Death Differ; 2010 Apr; 17(4):586-95. PubMed ID: 19893573
[TBL] [Abstract][Full Text] [Related]
15. Serpins prevent granzyme-induced death in a species-specific manner.
Bots M; VAN Bostelen L; Rademaker MT; Offringa R; Medema JP
Immunol Cell Biol; 2006 Feb; 84(1):79-86. PubMed ID: 16405655
[TBL] [Abstract][Full Text] [Related]
16. The intracellular granzyme B inhibitor, proteinase inhibitor 9, is up-regulated during accessory cell maturation and effector cell degranulation, and its overexpression enhances CTL potency.
Hirst CE; Buzza MS; Bird CH; Warren HS; Cameron PU; Zhang M; Ashton-Rickardt PG; Bird PI
J Immunol; 2003 Jan; 170(2):805-15. PubMed ID: 12517944
[TBL] [Abstract][Full Text] [Related]
17. Polydopamine-based nanoplatform for photothermal ablation with long-term immune activation against melanoma and its recurrence.
Li M; Guo R; Wei J; Deng M; Li J; Tao Y; Li M; He Q
Acta Biomater; 2021 Dec; 136():546-557. PubMed ID: 34536603
[TBL] [Abstract][Full Text] [Related]
18. Surface charge-modification prevents sequestration and enhances tumor-cell specificity of a recombinant granzyme B-TGFα fusion protein.
Jabulowsky RA; Oberoi P; Bähr-Mahmud H; Dälken B; Wels WS
Bioconjug Chem; 2012 Aug; 23(8):1567-76. PubMed ID: 22759275
[TBL] [Abstract][Full Text] [Related]
19. The functionalized human serine protease granzyme B/VEGF₁₂₁ targets tumor vasculature and ablates tumor growth.
Mohamedali KA; Cao Y; Cheung LH; Hittelman WN; Rosenblum MG
Mol Cancer Ther; 2013 Oct; 12(10):2055-66. PubMed ID: 23858102
[TBL] [Abstract][Full Text] [Related]
20. Reactive oxygen species / photothermal therapy dual-triggered biomimetic gold nanocages nanoplatform for combination cancer therapy via ferroptosis and tumor-associated macrophage repolarization mechanism.
Wei Y; Wang Z; Yang J; Xu R; Deng H; Ma S; Fang T; Zhang J; Shen Q
J Colloid Interface Sci; 2022 Jan; 606(Pt 2):1950-1965. PubMed ID: 34695762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
